metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	avelumab alone vs. paclitaxel	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
	pembrolizumab alone vs. paclitaxel	1	-777 [-1355; -199] /10000 239/296 vs. 262/296	34 [-402; 469] /10000 273/296 vs. 272/296	-
versus placebo
	nivolumab alone vs. placebo	1	-1802 [-2527; -1076] /10000 226/330 vs. 141/163	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone vs. paclitaxel	1	NaN [NaN; NaN] /10000 0/0 vs. 0/0	-216 [-769; 338] /10000 177/196 vs. 184/199	-